Skip to main content
. 2017 Dec 22;11(3):261–266. doi: 10.1111/cts.12532

Figure 2.

Figure 2

Elotuzumab mechanism of action. Elotuzumab primarily acts by activating natural killer (NK) cell–mediated killing of myeloma cells via antibody‐dependent cellular cytotoxicity (A). Elotuzumab also directly activates NK cells to kill myeloma cells (B). EAT‐2, Ewing's sarcoma‐associated transcript 2; SLAMF7, signaling lymphocytic activation molecule F7. Figure from Lonial, S. et al. Expert Opin. Biol. Ther. 16, 1291–1301 (2016). Reprinted with permission from Taylor & Francis © 2016.